Celsus, Inc., a closely-held enterprise founded in 1987, has as its mission the manufacture of heparin derivatives and the development of novel carbohydrates for medical and biomedical needs unmet by heparin. Celsus Laboratories, Inc., its wholly-owned subsidiary, operates a U.S. Food and Drug Administration (FDA)-inspected bulk drug facility in Cincinnati and manufactures and markets more than a dozen heparin derivatives for use in products formulated for the prevention and treatment of thrombo-embolism, cardiac surgery, extracorporeal procedures, catheter lock-flush, blood-interacting medical devices, and affinity chromatograpy.